STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo’s (STO:ORXA) product for nocturia and on demand treatment of urinary incontinence, OX 19 (sublingual desmopressin) has started phase 1 trials. Orexo has developed several formulations and is now proceeding to investigate the lead formulation. The bioavailability trial, which is taking place in Sweden, is expected to be completed by the end of this year. OX 19 exploits Orexo’s novel sublingual tablet technology which enables rapid and reliable onset of action.
